Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria

Authors:

Abstract
Background and Aim: This study aimed to compare the therapeutic effects and safety of lenvatinib (LEN) plus transcatheter arterial chemoembolization (LEN‐TACE) and atezolizumab plus bevacizumab (Atez/Bev) as the first‐line therapies in patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond the up‐to‐seven criteria.Methods: We enrolled 768 patients with HCC treated with first‐line systemic therapy, and 154 patients were enrolled and categorized into either the LEN‐TACE therapy (n = 42) or Atez/Bev (n = 112) groups. After propensity score matching (PSM), 72 patients (LEN‐TACE group, n = 36; Atez/Bev group, n = 36) were analyzed.Results: After PSM, the median progression‐free survival showed no significant differences between the LEN‐TACE and Atez/Bev groups (8.5 [95% confidence interval (CI): 6.1–10.7] months vs. 8.6 (95% CI: 5.3–12.1) months, respectively; p = 0.973). Regarding median overall survival (OS), no significant differences were noted between the LEN‐TACE and Atez/Bev groups (37.3 [95% CI: 31.2–60.2] months vs. 32.4 (95% CI: 19.5–NE) months, respectively; p = 0.183). Regarding adverse events (AEs) of grade ≥ 3, no significant difference was observed between the two groups. Multivariate analysis revealed that the ALBI grade 1 and low AFP levels were independent factors for OS.Conclusion: LEN‐TACE therapy may be one of the effective treatment strategies in intermediate‐stage HCC patients beyond the up‐to‐seven criteria.

This publication has 24 references indexed in Scilit: